{
  "meta": {
    "title": "00202_Mid_Day_Pyqs_Neet_Pg_-_Final_18",
    "url": "https://brainandscalpel.vercel.app/00202-mid-day-pyqs-neet-pg-final-18-cb81ffe3.html",
    "scrapedAt": "2025-11-29T18:14:08.899Z"
  },
  "questions": [
    {
      "id": 73073,
      "choices": [
        {
          "id": 291257,
          "text": "<p><span style=\"font-size:16px;\">Biguanides</span></p>"
        },
        {
          "id": 291258,
          "text": "<p><span style=\"font-size:16px;\">GLP-1 receptor agonists</span></p>"
        },
        {
          "id": 291259,
          "text": "<p><span style=\"font-size:16px;\">SGLT-2 inhibitors</span></p>"
        },
        {
          "id": 291260,
          "text": "<p><span style=\"font-size:16px;\">Sulfonylureas</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">Which of the following antidiabetic drugs is preferred in a patient with heart and kidney disease? (FMGE JAN 2025)</span></p>",
      "unique_key": "Q7011056",
      "question_audio": null,
      "question_video": null,
      "map_id": 26885763,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. C) SGLT-2 inhibitors</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>SGLT-2 inhibitors</strong> (e.g., <strong>dapagliflozin, empagliflozin, canagliflozin</strong>) are the <strong>preferred first-line agents</strong> in diabetic patients with <strong>heart and kidney disease</strong> because they:</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\"><strong>Reduce major adverse cardiovascular events</strong></span></li><li><span style=\"font-size:16px;\"><strong>Decrease heart failure hospitalizations</strong></span></li><li><span style=\"font-size:16px;\"><strong>Slow progression of diabetic kidney disease</strong></span></li><li><span style=\"font-size:16px;\"><strong>Reduce proteinuria and lower blood pressure</strong></span></li><li><span style=\"font-size:16px;\"><strong>Provide cardio-protection independent of glucose control</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. Biguanides (Metformin):</strong> While <strong>first-line for type 2 diabetes</strong>, it does not provide <strong>cardiovascular benefits</strong> and requires <strong>caution in kidney disease</strong> due to the risk of <strong>lactic acidosis</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option B. GLP-1 receptor agonists:</strong> While <strong>cardioprotective</strong>, they <strong>do not provide as strong heart failure or renal benefits</strong> as <strong>SGLT-2 inhibitors</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. Sulfonylureas:</strong> Not preferred because:</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\"><strong>High risk of hypoglycemia</strong>, especially in renal disease</span></li><li><span style=\"font-size:16px;\">No proven cardiovascular benefits</span></li><li><span style=\"font-size:16px;\">Possible increased cardiovascular risk with certain sulfonylureas</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>SGLT-2 inhibitors are the preferred antidiabetic agents</strong> in patients with <strong>heart failure and chronic kidney disease (CKD)</strong> due to their <strong>proven cardiovascular and renal benefits</strong>.</span></p>",
      "correct_choice_id": 291259,
      "solution_audio": null,
      "solution_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/73073/FMGE_Jan_2025_Medicine_Q_-_11.mp4",
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "top",
      "tags": [
        "Factual",
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/73073/FMGE_Jan_2025_Medicine_Q_-_11.mp4",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57176,
      "choices": [
        {
          "id": 228093,
          "text": "<p><span style=\"font-size:12.0pt;\">Teratoma</span></p>"
        },
        {
          "id": 228094,
          "text": "<p><span style=\"font-size:12.0pt;\">Endometrioma</span></p>"
        },
        {
          "id": 228095,
          "text": "<p><span style=\"font-size:12.0pt;\">Carcinoma ovary</span></p>"
        },
        {
          "id": 228096,
          "text": "<p><span style=\"font-size:12.0pt;\">Dysgerminoma</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A lady presented with a pelvic mass which was hyperintense on T1-weighted image, hyperintense on T1-fat saturated image, and hypointense on T2-weighted image with T2 shading. What is the likely diagnosis? (NEET PG 2024)</span></p>",
      "unique_key": "Q1673575",
      "question_audio": null,
      "question_video": null,
      "map_id": 26886286,
      "difficulty_level": "intermediate",
      "subjects_id": [
        17
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Endometrioma</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The imaging findings described are characteristic of an endometrioma. Endometriomas are cystic ovarian lesions filled with old blood, often referred to as \"chocolate cysts.\" On MRI, these lesions typically appear hyperintense on T1-weighted images due to the presence of subacute or chronic blood products. On T1-fat saturated images, the mass remains hyperintense, confirming that the hyperintensity is due to blood rather than fat. The hallmark feature of an endometrioma is the T2 shading sign, which refers to the gradual decrease in signal intensity on T2-weighted images due to repeated hemorrhage and layering of blood products within the cyst.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Teratoma</strong>: Teratomas often contain fat, which would appear hyperintense on T1-weighted images but would become hypointense on T1-fat saturated sequences. The lack of T2 shading and persistence of T1 hyperintensity on fat saturation sequences make this diagnosis unlikely.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Carcinoma ovary</strong>: Carcinoma of the ovary usually appears as a solid or complex cystic mass with variable signal characteristics. It does not typically present with T1 hyperintensity due to fat or blood nor does it show T2 shading.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Dysgerminoma</strong>: Dysgerminomas are solid ovarian tumors that do not exhibit hyperintensity on T1-weighted images or T2 shading. They usually appear as large, solid masses with homogeneous or slightly heterogeneous signal intensities on MRI.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Endometriomas are characterized by T1 hyperintensity that persists on T1-fat saturated images and display the T2 shading sign, distinguishing them from other ovarian masses.</span></p>",
      "correct_choice_id": 228094,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57646,
      "choices": [
        {
          "id": 229953,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clear cell carcinoma</span></span></p>"
        },
        {
          "id": 229954,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Papillary carcinoma</span></span></p>"
        },
        {
          "id": 229955,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chromophobe carcinoma</span></span></p>"
        },
        {
          "id": 229956,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bellini duct carcinoma</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 58-year-old man presents to the clinic with a history of unexplained weight loss, hematuria, and a palpable abdominal mass. Imaging studies reveal a large renal mass. A renal biopsy has the following finding. What is the likely diagnosis? (NEET PG 2024)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/19/pathology-neet-pg-aug-2024-pdf16.jpg\" style=\"height:174px; width:400px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>",
      "unique_key": "Q6824004",
      "question_audio": null,
      "question_video": null,
      "map_id": 26886287,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Chromophobe carcinoma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation and biopsy findings are consistent with chromophobe renal cell carcinoma (RCC). Chromophobe RCC is characterized histologically by large polygonal cells with distinct cell borders<strong>, perinuclear halos, and a &quot;plant-like&quot; or &quot;resinoid&quot; nuclear appearance</strong>. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The biopsy image shows these classic features, which differentiate chromophobe RCC from other renal cancer variants.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While clear cell carcinoma is the most common type of RCC, the histological findings of clear cytoplasm with perinuclear clearing are more characteristic of chromophobe carcinoma. This variant is less aggressive compared to clear cell RCC and is often diagnosed with specific features on histopathology.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Clear cell carcinoma:</span></strong><span style=\"font-size:12.0pt\"> This is the most common type of RCC, characterized by cells with clear cytoplasm due to the presence of glycogen and lipid, which are dissolved during processing. The biopsy image does not show these clear cells, ruling out this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Papillary carcinoma:</span></strong><span style=\"font-size:12.0pt\"> Papillary RCC is characterized by the presence of papillary structures and foamy macrophages. The biopsy image lacks these papillary features, making this diagnosis unlikely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Bellini duct carcinoma:</span></strong><span style=\"font-size:12.0pt\"> Also known as collecting duct carcinoma, this rare and aggressive form of RCC shows infiltrative growth patterns with prominent desmoplastic reaction. The biopsy does not match these characteristics.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chromophobe RCC is identified by cells with distinct borders, a plant-like or resinoid nucleus, and a perinuclear halo, distinguishing it from other RCC types.</span></span></p>",
      "correct_choice_id": 229955,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14547,
      "choices": [
        {
          "id": 58149,
          "text": "<p><span style=\"font-size:12.0pt;\">Foley's catheterization</span></p>"
        },
        {
          "id": 58150,
          "text": "<p><span style=\"font-size:12.0pt;\">Ascending urethrogram</span></p>"
        },
        {
          "id": 58151,
          "text": "<p><span style=\"font-size:12.0pt;\">Nephrogram</span></p>"
        },
        {
          "id": 58152,
          "text": "<p><span style=\"font-size:12.0pt;\">Suprapubic cystostomy</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 22-year-old man presents to the emergency department after a fall from height. The patient reports no pain or injury, but on examination, there is blood at the tip of the urethral meatus. The patient is hemodynamically stable with no other injuries. The next step in management would be? (NEET PG 2021)</span></p>",
      "unique_key": "Q1712719",
      "question_audio": null,
      "question_video": null,
      "map_id": 26886289,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B) Ascending urethrogram</strong></span></p><p style=\"margin-left:24px;\">&nbsp;</p><ul><li><span style=\"font-size:12pt;\">The clinical scenario suggests a suspected urethral injury with blood at the urethral meatus, which is commonly caused by external trauma or instrumentation.</span></li><li><span style=\"font-size:12pt;\">&nbsp;To confirm urethral rupture, the next step would be an ascending urethrogram.</span></li><li><span style=\"font-size:12pt;\"><strong>Ascending urethrogram:&nbsp;</strong>Correct. In a patient who is hemodynamically stable and without symptoms of a full bladder, retrograde urethrography will help determine the extent of the injury and decide on the next appropriate steps.</span></li></ul><p style=\"margin-left:24px;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Foley's catheterization:&nbsp;</strong>In the setting of suspected urethral injury, as evidenced by the presence of blood at the tip of the urethral meatus, inserting a Foley catheter can be harmful. It could potentially exacerbate the injury or convert a partial tear into a complete one. Hence, this is contraindicated without first confirming the integrity of the urethra.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Nephrogram:&nbsp;</strong>A nephrogram is an imaging study of the kidneys and their function. While it can give details about the upper urinary tract, it's not typically used for evaluating urethral injuries.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Suprapubic cystostomy:&nbsp;</strong>Suprapubic cystostomy, or suprapubic catheter placement, involves inserting a catheter directly into the bladder through the abdominal wall. It's done to divert urine when urethral catheterization is not possible or contraindicated, such as in the setting of a known or suspected urethral injury. This will be attempted after an urethrogram confirms a rupture.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">To confirm urethral rupture in a patient with suspected urethral injury, an ascending urethrogram is the next step in management.</span></li><li><span style=\"font-size:12pt;\">Foley's catheterization should be avoided as it may exacerbate the injury.</span></li></ul>",
      "correct_choice_id": 58150,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5315,
      "choices": [
        {
          "id": 21232,
          "text": "<p><span style=\"font-size:12.0pt;\">Cytomegalovirus</span></p>"
        },
        {
          "id": 21233,
          "text": "<p><span style=\"font-size:12.0pt;\">JC virus</span></p>"
        },
        {
          "id": 21234,
          "text": "<p><span style=\"font-size:12.0pt;\">BK virus</span></p>"
        },
        {
          "id": 21235,
          "text": "<p><span style=\"font-size:12.0pt;\">Epstein-Barr virus</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Which of the following is the predominant pathogen to infect the renal transplant recipients in the period around 1 to 4 months following the transplantation<strong>?</strong></span><span style=\"font-size:10.5pt;\"> (</span><span style=\"font-size:12.0pt;\">NEET PG 2020)</span></p>",
      "unique_key": "Q9572899",
      "question_audio": null,
      "question_video": null,
      "map_id": 26886291,
      "difficulty_level": "beginner",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Cytomegalovirus</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The predominant pathogen to infect the renal transplant recipients in the period around 1 to 4 months following the transplantation is cytomegalovirus (CMV).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The most common CMV presentation in kidney transplant patients is fever, leukopenia, hepatosplenomegaly, myalgia, and arthralgia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">JC virus, BK virus, and Epstein-Barr virus also have the propensity to cause infections during this period, but in lesser frequencies than CMV.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. JC Virus:</strong> Known for causing progressive multifocal leukoencephalopathy (PML), especially in patients with severe immunodeficiency, but it is less common than CMV in affecting renal transplant patients in the early months post-transplant.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. BK Virus:</strong> This virus can affect renal transplant recipients by causing BK virus-associated nephropathy, which can lead to graft dysfunction and loss. However, its peak incidence typically occurs slightly later than CMV.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Epstein-Barr Virus (EBV):</strong> While EBV can cause post-transplant lymphoproliferative disorder (PTLD), it is not as commonly the predominant pathogen in the early post-transplant period compared to CMV.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Recognizing and managing CMV infection in the early months following renal transplantation is crucial due to its potential to cause significant morbidity and impact on graft survival. Monitoring for CMV activity and initiating pre-emptive or therapeutic antiviral treatment as indicated is key to improving transplant outcomes.</span></p>",
      "correct_choice_id": 21232,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55425,
      "choices": [
        {
          "id": 221161,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Chloroquine</span></span></p>"
        },
        {
          "id": 221162,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Artemesinin combination therapy</span></span></p>"
        },
        {
          "id": 221163,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">IV artesunate</span></span></p>"
        },
        {
          "id": 221164,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Primaquine</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A 35-year-old male presented with fever, confusion, and altered mental status. On examination, he has jaundice, reduced urine output, low BP, and a feeble pulse. Lab studies reveal severe anemia, thrombocytopenia, and elevated liver enzymes. Peripheral smear revealed P. falciparum. What is the best treatment?<strong> </strong>(FMGE JULY 2024)</span></span></p>",
      "unique_key": "Q3947884",
      "question_audio": null,
      "question_video": null,
      "map_id": 26885759,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C) IV artesunate</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The patient presents with severe falciparum malaria, indicated by symptoms such as fever, confusion, jaundice, reduced urine output, low blood pressure, and laboratory findings including severe anemia, thrombocytopenia, and elevated liver enzymes. Plasmodium falciparum is confirmed on a peripheral smear. Severe falciparum malaria is a medical emergency that requires prompt and effective treatment.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Key treatment guidelines: IV artesunate</strong> is the first-line treatment for severe malaria caused by Plasmodium falciparum in non-pregnant adults. It acts rapidly and is effective in reducing parasitemia and improving clinical outcomes.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Once the patient&#39;s condition stabilizes and improves, the therapy is typically completed with an artemisinin-based combination therapy (ACT).</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">If IV artesunate is unavailable, then the alternative treatment is IV Quinine. After this, once the patient shows improvement, the treatment should be followed up with oral quinine combined with either doxycycline or clindamycin to complete the therapy. This approach ensures a comprehensive treatment regimen for severe malaria, with IV artesunate being the most recommended initial treatment due to its efficacy.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Chloroquine:</strong> This drug is not effective against Plasmodium falciparum due to widespread resistance.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Artemesinin combination therapy (ACT):</strong> While ACT is used to complete the treatment after initial stabilization with IV artesunate, it is not the first-line treatment in severe cases.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Primaquine:</strong> This drug is used to eliminate the hypnozoite stages of Plasmodium vivax and Plasmodium ovale and is not the primary treatment for severe falciparum malaria. Although a single dose of primaquine is sometimes given to reduce transmission, it is not the mainstay of therapy in this scenario.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In cases of severe falciparum malaria, the first-line treatment is IV artesunate, followed by artemisinin combination therapy (ACT) once the patient stabilizes.</span></span></p>",
      "correct_choice_id": 221163,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54676,
      "choices": [
        {
          "id": 218169,
          "text": "<p><span style=\"font-size:12.0pt;\">1-a, 2-c, 3-b, 4-d</span></p>"
        },
        {
          "id": 218170,
          "text": "<p><span style=\"font-size:12.0pt;\">1-a, 2-b, 3-c, 4-d</span></p>"
        },
        {
          "id": 218171,
          "text": "<p><span style=\"font-size:12.0pt;\">1-d, 2-a, 3-b, 4-c</span></p>"
        },
        {
          "id": 218172,
          "text": "<p><span style=\"font-size:12.0pt;\">1-c, 2-b, 3-a, 4-d</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following&nbsp;(INICET MAY 2024)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/24/screenshot-2024-08-24-104329.png\" alt=\"\" width=\"1000\" height=\"213\"></span></p>",
      "unique_key": "Q7376940",
      "question_audio": null,
      "question_video": null,
      "map_id": 26885757,
      "difficulty_level": "beginner",
      "subjects_id": [
        16
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>B) 1-a, 2-b, 3-c, 4-d</strong></span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\"><strong>Eonism:</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>a. Sexual gratification by cross-dressing. </strong>This term is used to describe individuals who derive sexual pleasure from dressing in clothes traditionally worn by the opposite gender.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Frotteurism:</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>b. The act of rubbing one's genitals against a non-consenting person,</strong> usually in a crowded place, such as public transport. It is considered a paraphilic disorder.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Necrophilia:</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>c. Sexual stimulation by corpses</strong>. This is a rare and extreme paraphilia where individuals are sexually aroused by deceased bodies.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Algolagnia:</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>d. Sexual gratification in inflicting or suffering pain</strong>. This can involve either sadism (inflicting pain) or masochism (receiving pain) as part of sexual activity.</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Eonism is sexual gratification by cross-dressing, frotteurism involves rubbing genitals against a non-consenting person, necrophilia is sexual stimulation by corpses, and algolagnia involves sexual gratification from inflicting or suffering pain.</span></p>",
      "correct_choice_id": 218170,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54285,
      "choices": [
        {
          "id": 216609,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased Renal Blood Flow</span></p>"
        },
        {
          "id": 216610,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased Glomerular hydrostatic pressure</span></p>"
        },
        {
          "id": 216611,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased Bowman's oncotic pressure</span></p>"
        },
        {
          "id": 216612,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased Glomerular oncotic pressure</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A decrease in GFR is associated with which of the following?</span>&nbsp;(INICET MAY 2024)</p>",
      "unique_key": "Q3009609",
      "question_audio": null,
      "question_video": null,
      "map_id": 26885756,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Decreased Bowman's oncotic pressure</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">If the hydrostatic pressure of the capillaries or the oncotic pressure of the Bowman's capsule decreases, filtration will decrease. If the oncotic pressure in the glomerular capillary increases or if the hydrostatic pressure in the Bowman's capsule increases, GFR will decrease as well.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Glomerular filtration rate (GFR) is determined by the net filtration pressure, which depends on various pressures within the glomerulus and Bowman's capsule:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Increased Renal Blood Flow:</strong> This increases GFR as more blood flow leads to higher filtration.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Increased Glomerular Hydrostatic Pressure:</strong> This also increases GFR because higher pressure in the glomerulus drives more filtrate into Bowman's capsule.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Decreased Glomerular Oncotic Pressure:</strong> This increases GFR because lower protein concentration in the glomerulus reduces the opposing force to filtration.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Decreased Bowman's capsule oncotic pressure reduces net filtration pressure (NFP) and decreases glomerular filtration rate (GFR). Increased Bowman's capsule oncotic pressure increases filtration pressure and GFR.</span></p>",
      "correct_choice_id": 216611,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 47642,
      "choices": [
        {
          "id": 190179,
          "text": "<p><span style=\"font-size:12.0pt;\">QT prolongation</span></p>"
        },
        {
          "id": 190180,
          "text": "<p><span style=\"font-size:12.0pt;\">PR prolongation</span></p>"
        },
        {
          "id": 190181,
          "text": "<p><span style=\"font-size:12.0pt;\">ST elevation</span></p>"
        },
        {
          "id": 190182,
          "text": "<p><span style=\"font-size:12.0pt;\">Wide QRS</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the likely ECG change associated with Bedaquiline?</span></p>",
      "unique_key": "Q7842035",
      "question_audio": null,
      "question_video": null,
      "map_id": 26885758,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) QT prolongation</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Bedaquiline is a modern anti-tubercular drug used primarily for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. One of the significant side effects of bedaquiline is QT prolongation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">QT prolongation is a measure of delayed ventricular repolarization, which can be seen on an ECG as an extended QT interval. This side effect is critical as it can predispose patients to potentially fatal arrhythmias, such as Torsades de Pointes.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. PR prolongation</strong>: This represents delayed atrioventricular conduction and is not a known side effect of bedaquiline.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. ST elevation</strong>: This is typically associated with myocardial infarction and is not a side effect of bedaquiline.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Wide QRS</strong>: This indicates delayed intraventricular conduction and is not associated with bedaquiline.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Bedaquiline, an important drug for treating MDR and XDR tuberculosis, is known for causing QT prolongation on ECG.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Note -</strong> <strong>The \"Q\" in bedaquiline can be a mnemonic to remember this important side effect.</strong></span></p>",
      "correct_choice_id": 190179,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 73626,
      "choices": [
        {
          "id": 293445,
          "text": "<p><span style=\"font-size:16px;\">Cellular swelling</span></p>"
        },
        {
          "id": 293446,
          "text": "<p><span style=\"font-size:16px;\">Bleb formation</span></p>"
        },
        {
          "id": 293447,
          "text": "<p><span style=\"font-size:16px;\">Amorphous density of mitochondria</span></p>"
        },
        {
          "id": 293448,
          "text": "<p><span style=\"font-size:16px;\">Cytoplasmic vacuolation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">A tissue sample shows significant cellular damage. Which of the following changes is most indicative of irreversible cell injury in the sample? (FMGE JAN 2025)</span></p>",
      "unique_key": "Q2633599",
      "question_audio": null,
      "question_video": null,
      "map_id": 26885761,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. C) Amorphous density of mitochondria</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">Amorphous densities in mitochondria are characteristic features of <strong>irreversible cell injury.</strong> These densities represent calcium phosphate deposits within damaged mitochondria, which occur as the mitochondrial membrane becomes increasingly permeable during severe cell injury. When mitochondria are severely damaged, they can no longer maintain calcium homeostasis, leading to calcium influx and the formation of these dense deposits.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. Cellular swelling:</strong> This is an early change that can be seen in <strong>both reversible and irreversible cell injury</strong>. It occurs due to the failure of the sodium-potassium pump resulting in sodium accumulation within the cell, followed by water influx. Since this is a nonspecific finding that can be present in <strong>both reversible and irreversible injury,</strong> it's not the most indicative of irreversible damage.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option B. Bleb formation:</strong> Blebs are outpouchings of the plasma membrane that form due to <strong>focal weakening of the cytoskeleton.</strong> Like cellular swelling, bleb formation can be seen in both reversible and irreversible cell injury, so it's not specifically indicative of irreversible damage.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. Cytoplasmic vacuolation:</strong> Vacuoles can form in the cytoplasm during cell injury due to dilation of the endoplasmic reticulum or increased autophagy. This change is commonly seen in reversible cell injury and is therefore not the most reliable indicator of irreversible damage.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The presence of amorphous densities in mitochondria is a morphological feature that indicates irreversible cell injury, distinguishing it from changes that can be seen in both reversible and irreversible injury such as <strong>cellular swelling, bleb formation, and cytoplasmic vacuolation.</strong></span></p>",
      "correct_choice_id": 293447,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6033,
      "choices": [
        {
          "id": 24102,
          "text": "<p><span style=\"font-size:12pt;\">Elemental calcium of 1200mg/ day is recommended</span></p>"
        },
        {
          "id": 24103,
          "text": "<p><span style=\"font-size:12pt;\">Oral vit D3 is to be given with calcium</span></p>"
        },
        {
          "id": 24104,
          "text": "<p><span style=\"font-size:12pt;\">Teriparatide is to be started first if treatment with teriparatide and bisphosphonates is being considered</span></p>"
        },
        {
          "id": 24105,
          "text": "<p><span style=\"font-size:12pt;\">Bisphosphonates should not be given for more than 1 year</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year post-menopausal obese lady presents with backache. She has a history of Colle’s fracture 1 year back. A DEXA scan shows a T score of less than - 2.5. Which of the following is false?</span>&nbsp;(NEET PG 2021)</p>",
      "unique_key": "Q7807160",
      "question_audio": null,
      "question_video": null,
      "map_id": 26886294,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D) Bisphosphonates should not be given for more than 1 year</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Management of Osteoporosis:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Elemental Calcium and Vitamin D:</strong></span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">Postmenopausal women are recommended to take 1200 mg/day of elemental calcium along with 400-800 IU of vitamin D to help maintain bone health and reduce the risk of fractures.</span></li></ul></li><li><span style=\"font-size:12pt;\"><strong>Bisphosphonates:</strong></span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">Bisphosphonates such as Alendronate, Risedronate, Ibandronate, and Zoledronic acid are commonly used to treat osteoporosis. These drugs help to slow down bone resorption, thus preserving bone density.</span></li><li><span style=\"font-size:12pt;\">The recommended duration of bisphosphonate therapy is generally 3-5 years, not limited to just 1 year. Studies have shown that longer-term use of bisphosphonates can continue to provide benefits in reducing the risk of fractures. However, the exact duration should be individualized based on the patient's risk factors and response to treatment.</span></li></ul></li><li><span style=\"font-size:12pt;\"><strong>Teriparatide:</strong></span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">Teriparatide is a recombinant form of parathyroid hormone that stimulates new bone formation. It is particularly beneficial in patients with severe osteoporosis or those who have not responded well to bisphosphonates.</span></li><li><span style=\"font-size:12pt;\"><strong>When considering treatment with both teriparatide and bisphosphonates, it is often recommended to start with teriparatide first to build bone and then follow with bisphosphonates to maintain the bone density gains achieved with teriparatide.</strong></span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Elemental calcium of 1200mg/day is recommended:&nbsp;</strong>This statement is true. Adequate calcium intake is essential for bone health, especially in postmenopausal women.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Oral vit D3 is to be given with calcium:&nbsp;</strong>This statement is true. Vitamin D3 helps in the absorption of calcium and is recommended to be given along with calcium supplements.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Teriparatide is to be started first if treatment with teriparatide and bisphosphonates is being considered:&nbsp;</strong>This statement is true. Starting with teriparatide helps build bone density, and following with bisphosphonates helps maintain the gains.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Bisphosphonates should not be given for more than 1 year:&nbsp;</strong>This statement is false. Bisphosphonates can be given for a longer duration, typically 3-5 years, depending on the patient's individual risk factors and response to therapy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Bisphosphonates are typically recommended for a duration of 3-5 years in the treatment of osteoporosis, not limited to just 1 year.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 500, Williams Gynecology 3<sup>rd</sup> edition</strong></span></p>",
      "correct_choice_id": 24105,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 56073,
      "choices": [
        {
          "id": 223717,
          "text": "<p><span style=\"font-size:12.0pt;\">Arsenic</span></p>"
        },
        {
          "id": 223718,
          "text": "<p><span style=\"font-size:12.0pt;\">Mercury</span></p>"
        },
        {
          "id": 223719,
          "text": "<p><span style=\"font-size:12.0pt;\">Lead</span></p>"
        },
        {
          "id": 223720,
          "text": "<p><span style=\"font-size:12.0pt;\">Copper</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient presented with features as given in the image below.What is the likely &nbsp;diagnosis? (NEET PG 2024)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/05/screenshot-2024-09-05-173132.jpeg\" alt=\"\" width=\"700\" height=\"288\"></span></p>",
      "unique_key": "Q8935690",
      "question_audio": null,
      "question_video": null,
      "map_id": 26886298,
      "difficulty_level": "beginner",
      "subjects_id": [
        10
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) &nbsp;Arsenic</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The image shows characteristic features of arsenic poisoning, including Mees' lines (Aldrich Mees lines) on the nails, which are transverse white lines seen in cases of heavy metal poisoning, particularly arsenic and thallium. The skin findings, such as hyperpigmentation and \"raindrop\" appearance, are also commonly associated with chronic arsenic exposure. Even though thallium poisoning can also present with similar nail changes, arsenic is the best answer unless alopecia is specifically noted, which is more common in thallium poisoning.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Mercury</strong>: Mercury poisoning typically presents with symptoms such as tremors, psychological disturbances, and gingivitis, not with the distinct Mees' lines and skin changes seen here.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Lead</strong>: Lead poisoning commonly affects the nervous system and presents with symptoms like abdominal pain, constipation, and lead lines on the gums (Burton’s lines), not the nail and skin changes shown in the image.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Copper</strong>: Copper toxicity, such as Wilson's disease, typically presents with liver, neurological symptoms, and Kayser-Fleischer rings in the eyes, not with Mees' lines or the described skin pigmentation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Mees' lines and raindrop pigmentation of the skin are classic signs of arsenic poisoning. In the absence of alopecia, arsenic is the preferred diagnosis over thallium.</span></p>",
      "correct_choice_id": 223717,
      "solution_audio": null,
      "solution_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/56073/Neet_Pg_Aug_2024_Fmt_Q_16.mp4",
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "top",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "RecentNEETPG"
      ],
      "explanation_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/56073/Neet_Pg_Aug_2024_Fmt_Q_16.mp4",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 73701,
      "choices": [
        {
          "id": 293745,
          "text": "<p><span style=\"font-size:16px;\">1, 2 and 3</span></p>"
        },
        {
          "id": 293746,
          "text": "<p><span style=\"font-size:16px;\">1 and 3</span></p>"
        },
        {
          "id": 293747,
          "text": "<p><span style=\"font-size:16px;\">1, 2, 3 and 4</span></p>"
        },
        {
          "id": 293748,
          "text": "<p><span style=\"font-size:16px;\">3 and 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">Which of the following statements regarding the causes of fall in diastolic blood pressure is correct? (INICET NOV 2024)</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:16px;\">Loss of sympathetic outflow in the lumbar region</span></li><li><span style=\"font-size:16px;\">Antagonism of beta-1 adrenergic receptors</span></li><li><span style=\"font-size:16px;\">Blockade of alpha-1 adrenergic receptors</span></li><li><span style=\"font-size:16px;\">Antagonism of beta-2 adrenergic receptors</span></li></ol>",
      "unique_key": "Q7624698",
      "question_audio": null,
      "question_video": null,
      "map_id": 26885754,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. B) 1 and 3</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Explanation:</strong>&nbsp;</span></p><p><br><span style=\"font-size:16px;\">A fall in diastolic blood pressure primarily occurs due to vasodilation. Two mechanisms listed that cause vasodilation are:</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>1. Loss of sympathetic outflow in lumbar region</strong>: Sympathetic system causes vasoconstriction, so its loss leads to vasodilation</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>3. Blockade of alpha-1 adrenergic receptors</strong>: Alpha-1 receptors mediate vasoconstriction, so their blockade causes vasodilation</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p><br><span style=\"font-size:16px;\"><strong>2. Antagonism of beta-1 adrenergic receptors</strong>: Incorrect. Beta-1 blockade primarily affects heart rate and contractility, leading to decreased systolic blood pressure, not diastolic pressure.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>4. Antagonism of beta-2 adrenergic receptors</strong>: Incorrect. Beta-2 receptors mediate vasodilation, so their blockade would cause vasoconstriction and potentially increase diastolic pressure.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:16px;\">Diastolic blood pressure is primarily affected by vascular tone - vasodilation decreases it (through loss of sympathetic tone or alpha-1 blockade) while vasoconstriction increases it.</span></p>",
      "correct_choice_id": 293746,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 47602,
      "choices": [
        {
          "id": 190019,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemostasis, Inflammation, Proliferation, remodeling</span></span></span></p>"
        },
        {
          "id": 190020,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inflammation, Hemostasis, Proliferation, Remodeling&nbsp; </span></span></span></p>"
        },
        {
          "id": 190021,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Remodeling, Inflammation, Hemostasis, Proliferation</span></span></span></p>"
        },
        {
          "id": 190022,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inflammation, Hemostasis, Remodeling, Proliferation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the correct sequence of wound healing?</span></span></p>",
      "unique_key": "Q6648194",
      "question_audio": null,
      "question_video": null,
      "map_id": 26885762,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Hemostasis, Inflammation, Proliferation, remodeling</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The correct sequence of events in the wound healing process is hemostasis, inflammation, proliferation, and remodeling.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">1. Hemostasis:</span></strong><span style=\"font-size:12.0pt\"> This is the first step in wound healing, where bleeding is stopped by the formation of a blood clot. This involves vasoconstriction, platelet aggregation, and the activation of the coagulation cascade.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">2. Inflammation:</span></strong><span style=\"font-size:12.0pt\"> After hemostasis, the inflammatory phase begins, which involves the influx of inflammatory cells (neutrophils, macrophages) to the wound site. These cells remove debris, bacteria, and damaged tissue, setting the stage for the next phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">3. Proliferation:</span></strong><span style=\"font-size:12.0pt\"> In this phase, new blood vessels (angiogenesis) are formed, and fibroblasts proliferate and produce collagen, forming granulation tissue. This granulation tissue fills the wound and provides a matrix for the migration and proliferation of epithelial cells, leading to re-epithelialization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">4. Remodeling:</span></strong><span style=\"font-size:12.0pt\"> This is the final phase, where the newly formed collagen fibers are reorganized and cross-linked, leading to increased tensile strength. During this phase, the wound contracts, and excess cells and blood vessels are removed through apoptosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The correct sequence of events in wound healing is hemostasis (stopping bleeding), inflammation (influx of inflammatory cells), proliferation (formation of granulation tissue, angiogenesis, and re-epithelialization), and remodeling (reorganization and cross-linking of collagen fibers).</span></span></p>",
      "correct_choice_id": 190019,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5545,
      "choices": [
        {
          "id": 22152,
          "text": "<p><span style=\"font-size:12.0pt;\">Epidermophyton floccosum</span></p>"
        },
        {
          "id": 22153,
          "text": "<p><span style=\"font-size:12.0pt;\">Microsporum audonii</span></p>"
        },
        {
          "id": 22154,
          "text": "<p><span style=\"font-size:12.0pt;\">Trichophyton mentagrophytes</span></p>"
        },
        {
          "id": 22155,
          "text": "<p><span style=\"font-size:12.0pt;\">Microsporum gypseum</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In a case of tinea capitis, white powdery colonies were isolated from the hair specimen. The hair perforation test was positive on the isolate. Which of the following is the likely etiology?</span> <span style=\"font-size:12.0pt;\">(NEET PG 2021)</span></p>",
      "unique_key": "Q8005621",
      "question_audio": null,
      "question_video": null,
      "map_id": 26886293,
      "difficulty_level": "beginner",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Trichophyton mentagrophytes</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The identification of Trichophyton mentagrophytes as the causative agent in this case of tinea capitis is confirmed by the positive hair perforation test. This test is particularly valuable for differentiating between species of Trichophyton, as it assesses the fungus's ability to penetrate and degrade hair keratin.</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Hair Perforation Test:</strong> This diagnostic tool is used to differentiate Trichophyton mentagrophytes from Trichophyton rubrum, as T. mentagrophytes demonstrates the ability to perforate hair, causing surface erosion which gives a wedge-shaped appearance to the hair shaft. This is a key characteristic that helps in identifying the fungal species responsible for the infection.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Epidermophyton floccosum:</strong> Does not typically infect hair, more commonly associated with skin and nail infections.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Microsporum audouinii:</strong> Causes tinea capitis but does not show a positive result on the hair perforation test.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Microsporum gypseum:</strong> Another cause of tinea capitis but also does not typically show a positive hair perforation test.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In cases of tinea capitis, a positive hair perforation test indicative of surface erosion and wedge-shaped appearance of the hair shaft confirms the presence of Trichophyton mentagrophytes. This test is crucial for distinguishing it from other dermatophytes, specifically Trichophyton rubrum.</span></p>",
      "correct_choice_id": 22154,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4578,
      "choices": [
        {
          "id": 18288,
          "text": "<p><span style=\"font-size:12.0pt;\">Albinism</span></p>"
        },
        {
          "id": 18289,
          "text": "<p><span style=\"font-size:12.0pt;\">G-6-PD deficiency</span></p>"
        },
        {
          "id": 18290,
          "text": "<p><span style=\"font-size:12.0pt;\">Marfan's syndrome</span></p>"
        },
        {
          "id": 18291,
          "text": "<p><span style=\"font-size:12.0pt;\">Lesch-Nyhan syndrome</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following diseases have autosomal recessive inheritance? (NEET PG 2019)</span></p>",
      "unique_key": "Q6563962",
      "question_audio": null,
      "question_video": null,
      "map_id": 26886290,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Albinism</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Albinism&nbsp;</strong>is typically inherited in an autosomal recessive manner. To have albinism, an individual must inherit two copies of the mutated gene for albinism, one from each parent.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. G-6-PD deficiency:&nbsp;</strong>Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is inherited in an X-linked recessive manner, not autosomal recessive. It affects males more often than females.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Marfan's syndrome:&nbsp;</strong>Marfan's syndrome is inherited in an autosomal dominant manner, not autosomal recessive. A single copy of the mutated gene from one parent is enough to cause the condition.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Lesch-Nyhan syndrome:&nbsp;</strong>Lesch-Nyhan syndrome is inherited in an X-linked recessive manner. It primarily affects males who inherit the mutated gene from their carrier mothers.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/03/screenshot-2024-01-03-161554_K9X19gw.jpg\" alt=\"\" width=\"1000\" height=\"920\"></p>",
      "correct_choice_id": 18288,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4597,
      "choices": [
        {
          "id": 18364,
          "text": "<p><span style=\"font-size:12.0pt;\">Meningitis</span></p>"
        },
        {
          "id": 18365,
          "text": "<p><span style=\"font-size:12.0pt;\">Subarachnoid hemorrhage</span></p>"
        },
        {
          "id": 18366,
          "text": "<p><span style=\"font-size:12.0pt;\">Intraparenchymal hemorrhage</span></p>"
        },
        {
          "id": 18367,
          "text": "<p><span style=\"font-size:12.0pt;\">Hemorrhagic stroke</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient complains of neck stiffness and severe headache. The CT image shown below is suggestive of which of the following conditions?(NEET PG 2020)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/03/31/1_AU3tBup.jpg\" alt=\"\" width=\"250\" height=\"285\"></span></p>",
      "unique_key": "Q3167469",
      "question_audio": null,
      "question_video": null,
      "map_id": 26886296,
      "difficulty_level": "beginner",
      "subjects_id": [
        17
      ],
      "solution": "<p><span style=\"color:black;font-size:12.0pt;\"><strong>Ans. B. Subarachnoid hemorrhage</strong></span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:12.0pt;\">The given clinical scenario of a patient presenting with neck stiffness and severe headache with <strong>CT showing blood in the basal cistern</strong> suggests towards the diagnosis of subarachnoid hemorrhage (SAH).</span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:12.0pt;\">Subarachnoid hemorrhage (SAH) is an <strong>extra axial intracranial hemorrhage</strong> and denotes the presence of blood within the subarachnoid space. NCCT shows the hyperdense <strong>“star of death” appearance</strong>.</span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:12.0pt;\">The <strong>modified Fisher scale</strong> <strong>is a grading method for SAH as seen on</strong> <strong>non-contrast CT</strong> (NCCT). The Hunt and Hess scale is used to describe the severity of SAH and to predict survival.</span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:12.0pt;\"><strong>Option A:&nbsp;</strong>Meningitis can also present with neck stiffness and headache. NCCT would be normal. <strong>CE-MRI shows thickened enhancing meninges</strong>.</span></p><p><span style=\"font-size:10.5pt;\">&nbsp;</span></p><p><span style=\"color:black;font-size:12.0pt;\"><strong>Option C:&nbsp;</strong>Intraparenchymal hemorrhage is </span><span style=\"background-color:white;color:black;font-size:12.0pt;\"><strong>acute accumulation of blood within the parenchyma of the brain</strong></span><span style=\"color:black;font-size:12.0pt;\"> and on CT scan </span><span style=\"background-color:white;color:black;font-size:12.0pt;\">a hyperdense collection of blood, often with surrounding hypodense edema.</span></p><p>&nbsp;</p><p><span style=\"background-color:white;color:black;font-size:12.0pt;\"><strong>Option D:&nbsp;</strong>Hemorrhagic stroke is a <strong>broader classification</strong> and usually indicated IC bleed.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"background-color:white;color:#0d0d0d;font-size:12.0pt;\">Subarachnoid hemorrhage is a critical condition indicated by CT findings of blood in the subarachnoid space, presenting clinically with rapid onset headache and neck stiffness. It requires immediate medical attention and further evaluation with grading scales like the modified Fisher scale to assess severity and guide treatment.</span></p>",
      "correct_choice_id": 18365,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15548,
      "choices": [
        {
          "id": 62152,
          "text": "<p><span style=\"font-size:12.0pt;\">Multiple enchondromatosis</span></p>"
        },
        {
          "id": 62153,
          "text": "<p><span style=\"font-size:12.0pt;\">Multiple Brown Tumour</span></p>"
        },
        {
          "id": 62154,
          "text": "<p><span style=\"font-size:12.0pt;\">Multiple Osteophytic Growth</span></p>"
        },
        {
          "id": 62155,
          "text": "<p><span style=\"font-size:12.0pt;\">None of the above</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A patient presented with multiple swelling in hand &amp; wrist. Finger X-ray is given. Identify: (NEET PG 2022)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/05/11/1.jpg\" alt=\"\" width=\"254\" height=\"303\"></span></p>",
      "unique_key": "Q1017168",
      "question_audio": null,
      "question_video": null,
      "map_id": 26886297,
      "difficulty_level": "beginner",
      "subjects_id": [
        15
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Multiple enchondromatosis</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>ENCHONDROMA</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">When chondromas arise in the medullary canal, they’re referred to as enchondroma.</span></li><li><span style=\"font-size:12.0pt;\">Enchondroma is benign tumor of short tubular bones of the hand.</span></li><li><span style=\"font-size:12.0pt;\">They are seen after age of skeletal maturity.</span></li><li><span style=\"font-size:12.0pt;\">These are the centric, non-expansile or minimally expansile tumors with marginal sclerosis.</span></li><li><span style=\"font-size:12.0pt;\">Medullary cavity, Metaphysical tumour</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/02/picture44.jpg\" alt=\"\" width=\"200\" height=\"290\"></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Most common tumour of bones of hand and feet</strong></span></li><li><span style=\"font-size:12.0pt;\">&nbsp;5% premalignant</span></li><li><span style=\"font-size:12.0pt;\">Multiple enchondromas is also known as <strong>Ollier’s syndrome</strong>. There are multiple enchondromas all over the body.</span></li><li><span style=\"font-size:12.0pt;\">Multiple enchondromas + subcutaneous Hemangioma + Phlebolith (Calcified superficial veins) = Maffucci syndrome</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/02/picture45.jpg\" alt=\"\" width=\"400\" height=\"209\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Maffucci syndrome: A) Hemangiomas, B) Phleboliths and Enchondromas</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Malignant transformation to chondrosarcoma may occur in &lt; 2% solitary cases, 30% in ollier disease and 100% in maffucci’s syndrome.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Treatment:</strong> Extended Curettage + bone grafting</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Multiple brown tumor.</strong> It has been reported that 2-5% patients with primary hyperparathyroidism have brown tumor (osteitis fibrosa cystica). Bone brown tumor secondary to primary hyperparathyroidism (PHPT) is very rare, which is caused by massive secretion of PTH. First, a large amount of bone calcium is mobilized into blood, resulting in fibrous tissue hyperplasia in bone and leaky hemorrhage. Then, macrophage reactive hyperplasia resulted in phagocytosis of red blood cells and a large amount of hemosiderin is produced, thereby forming a brown nodule. The lesions are usually multiple, most commonly seen in ribs, clavicle, pelvis, long bones and mandibles while others are rare. The radiograph of brown tumor is often characterized by osteoporosis, thinning of cortical bone and multiple localized cystic bone destruction.</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/02/picture46.jpg\" alt=\"\" width=\"300\" height=\"313\"></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Multiple osteophytic growth.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Osteophytes</strong>&nbsp;are cartilage-capped bony proliferations that most commonly develop at the margins of a&nbsp;synovial joint&nbsp;as a response to articular cartilage damage, as seen very commonly in&nbsp;degenerative joint disease.&nbsp;Central osteophytes&nbsp;can develop from cartilage lesions within a joint. They are considered a hallmark of&nbsp;osteoarthritis. Osteophytes may be confused with&nbsp;syndesmophytes&nbsp;and&nbsp;enthesophytes. Small osteophytes are sometimes referred to as&nbsp;<strong>osteophytic lipping</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/02/picture47.jpg\" alt=\"\" width=\"250\" height=\"373\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The given image in the question shows multiple enchondromas in the hand.</span></p>",
      "correct_choice_id": 62152,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "ImageBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10465,
      "choices": [
        {
          "id": 41826,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum ferritin levels</span></p>"
        },
        {
          "id": 41827,
          "text": "<p><span style=\"font-size:12.0pt;\">HbA2 levels</span></p>"
        },
        {
          "id": 41828,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum folate levels</span></p>"
        },
        {
          "id": 41829,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum homocysteine levels</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A female patient presented with fatigue. Routine complete blood count analysis showed hemoglobin of 9 g/dL, MCV 60fL, and RBC count of 5.2 million. A peripheral smear showed microcytic hypochromic anemia. Which of the following is the next best investigation for this patient? (NEET PG 2022)</span></p>",
      "unique_key": "Q4495419",
      "question_audio": null,
      "question_video": null,
      "map_id": 26886288,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) HbA2 levels</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Question is testing applied knowledge. Mentzer’s index needs to be calculated&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">A peripheral blood smear with microcytic hypochromic cells and a Mentzer index of less than 13 indicates thalassemia. As a result, HbA2 levels (which are elevated in thalassemia) must be tested next.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The Mentzer index, also known as the MCV/RBC count, can be used to distinguish thalassemia from iron-deficiency anemia (IDA). In both IDA and thalassemia, MCV (mean corpuscular volume) and MCH (mean corpuscular hemoglobin) are low. RBC count may be normal in thalassemia but decreased in IDA. A lower RBC count in IDA indicates a smaller denominator, resulting in a higher MCV/RBC ratio.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Mentzer index is</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">More than 13 in iron-deficiency anemia</span></li><li><span style=\"font-size:12.0pt;\">Less than 13 in thalassemia</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Alpha- and beta-thalassemia are inherited disorders in which there is reduced production of alpha-globin or beta-globin chains, respectively. This leads to precipitation of the excess (unpaired) chains, interfering with red blood cell (RBC) production and survival.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Clinical features in thalassemia include anemia, jaundice, skeletal deformities including facial deformities, changes in body habits, growth impairment, and hepatosplenomegaly. Due to frequent blood transfusions, iron overload is also seen.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Peripheral smear is likely to show microcytic hypochromic anemia with target cells, teardrop cells, and some coarse basophilic stippling in certain cases.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Serum ferritin levels</strong>: Relevant for diagnosing iron deficiency anemia but less specific for thalassemia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Serum folate levels</strong>: Relevant for diagnosing macrocytic anemia due to folate deficiency, not typically useful for microcytic anemia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Serum homocysteine levels</strong>: Elevated in cases of vitamin B12 or folate deficiency, related to macrocytic anemia, not microcytic anemia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">For a patient presenting with microcytic hypochromic anemia and an RBC count suggesting thalassemia (Mentzer index &lt; 13), the next best investigation is to measure HbA2 levels to confirm the diagnosis of beta-thalassemia.</span></p>",
      "correct_choice_id": 41827,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54935,
      "choices": [
        {
          "id": 219201,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hyponatremia</span></span></span></p>"
        },
        {
          "id": 219202,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hypokalemia</span></span></span></p>"
        },
        {
          "id": 219203,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hypochloremia</span></span></span></p>"
        },
        {
          "id": 219204,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hypophosphatemia</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which is the most common electrolyte imbalance seen in pyloric stenosis?</span> (<span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">FMGE JULY 2024)</span></span></span></p>",
      "unique_key": "Q6079514",
      "question_audio": null,
      "question_video": null,
      "map_id": 26885760,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">B) Hypokalemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pyloric stenosis is a condition where the opening from the stomach to the small intestine (the pylorus) becomes narrowed. This causes severe vomiting, which leads to the loss of stomach acid (hydrochloric acid). The loss of hydrochloric acid results in a <strong>metabolic alkalosis</strong> state.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In addition to the loss of stomach acid, vomiting leads to the depletion of various electrolytes, including sodium, potassium, and chloride. Among these, <strong>hypokalemia</strong> (low potassium levels) is the most common and significant electrolyte imbalance seen in pyloric stenosis. The continuous vomiting depletes potassium levels more profoundly than other electrolytes, making hypokalemia the predominant issue.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\"><strong>Option A.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Hyponatremia</strong>: While sodium levels can be affected by vomiting, hyponatremia is not the most common or significant imbalance in pyloric stenosis. The primary issue revolves around potassium and chloride.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\"><strong>Option C.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Hypochloremia</strong>: Hypochloremia (low chloride levels) is indeed a significant consequence of pyloric stenosis due to the loss of hydrochloric acid in vomit. However, it is not as clinically critical as hypokalemia in this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\"><strong>Option D.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Hypophosphatemia</strong>: Phosphate levels are generally not significantly affected by pyloric stenosis and are not considered a major electrolyte disturbance in this context.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hypokalemia is the most common and clinically significant electrolyte imbalance seen in pyloric stenosis due to persistent vomiting and the loss of stomach acid.</span></span></span></p>",
      "correct_choice_id": 219202,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 73696,
      "choices": [
        {
          "id": 293725,
          "text": "<p><span style=\"font-size:16px;\">Palbociclib</span></p>"
        },
        {
          "id": 293726,
          "text": "<p><span style=\"font-size:16px;\">Rucaparib</span></p>"
        },
        {
          "id": 293727,
          "text": "<p><span style=\"font-size:16px;\">Vorinostat</span></p>"
        },
        {
          "id": 293728,
          "text": "<p><span style=\"font-size:16px;\">Ustekinumab</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">A 52-year-old female presents with metastatic breast cancer. She has previously undergone treatment with surgery, radiation, and multiple lines of chemotherapy, but her disease has progressed. Genetic testing reveals a BRCA1 mutation, indicating an impaired DNA repair mechanism. Her cancer is classified as HER2-negative and hormone receptor-positive. Given the genetic findings, her oncologist considers using a therapy that targets the PARP enzyme to exploit the DNA repair vulnerability of her cancer cells. Which of the following drugs would be appropriate to prescribe as a PARP inhibitor in this patient?&nbsp;(INICET NOV 2024)</span></p>",
      "unique_key": "Q3709707",
      "question_audio": null,
      "question_video": null,
      "map_id": 26885753,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. B) Rucaparib</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Explanation:&nbsp;</strong></span></p><p><br><span style=\"font-size:16px;\">Rucaparib is a PARP (Poly ADP-Ribose Polymerase) inhibitor. PARP inhibitors work by blocking DNA repair mechanisms in cancer cells. In patients with BRCA mutations (who already have impaired DNA repair), PARP inhibition leads to synthetic lethality and cell death. The name helps identify PARP inhibitors as they end in \"parib\" (from Poly ADP-Ribose Polymerase inhibitor).</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong>&nbsp;</span></p><p><br><span style=\"font-size:16px;\"><strong>Option A. Palbociclib:</strong> Incorrect. This is a cyclin-dependent kinase (CDK) 4/6 inhibitor used in hormone receptor-positive breast cancer. While it might be useful in this patient's case, it is not a PARP inhibitor.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option C. Vorinostat</strong>: Incorrect. This is a histone deacetylase inhibitor used in certain hematologic malignancies, not a PARP inhibitor.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. Ustekinumab</strong>: Incorrect. This is a monoclonal antibody against interleukins used in psoriasis and other autoimmune conditions, not a PARP inhibitor.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:16px;\">PARP inhibitors (drugs ending in \"parib\") are particularly effective in cancers with BRCA mutations due to their mechanism of synthetic lethality in cells with impaired DNA repair.</span><br>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Breast Cancer</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-03-08%20115210.jpg\" width=\"921\" height=\"522\"></strong></span></p>",
      "correct_choice_id": 293726,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6013,
      "choices": [
        {
          "id": 24022,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flap closure of foramen ovale</span></span></span></p>"
        },
        {
          "id": 24023,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patent ductus arteriosus</span></span></span></p>"
        },
        {
          "id": 24024,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Premature closure of the ductus arteriosus</span></span></span></p>"
        },
        {
          "id": 24025,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Premature closure of the ductus venosus</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year primigravida is on indomethacin (25mg TDS) for polyhydramnios till 35 weeks. What abnormality can the fetus have if she goes into labor now?</span></span><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">&nbsp;</span></span></span>(NEET PG 2021)</p>",
      "unique_key": "Q9340256",
      "question_audio": null,
      "question_video": null,
      "map_id": 26886295,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Premature closure of the ductus arteriosus </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Indomethacin and Fetal Effects:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Indomethacin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a non-selective cyclo-oxygenase inhibitor used in obstetrics primarily for two indications:</span></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polyhydramnios:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> To reduce the excessive amniotic fluid.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tocolytic in preterm labor:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> To delay preterm labor.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Indomethacin works by inhibiting the production of prostaglandins, which are important for maintaining the patency of the ductus arteriosus in the fetus.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Risks:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When used beyond 32 weeks of gestation, indomethacin can cause <strong>premature closure of the ductus arteriosus</strong>, leading to complications such as:</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary hypertension</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Right ventricular hypertrophy</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heart failure</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Flap closure of foramen ovale:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The foramen ovale normally closes soon after birth when the pressure in the left atrium exceeds the pressure in the right atrium. Indomethacin does not affect the closure of the foramen ovale.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Patent ductus arteriosus:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patent ductus arteriosus (PDA) is a condition where the ductus arteriosus remains open after birth. Indomethacin is actually used to treat PDA by promoting its closure, not causing it.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Premature closure of the ductus venosus:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The ductus venosus allows oxygenated blood from the umbilical vein to bypass the liver and flow directly into the inferior vena cava. Indomethacin does not influence the closure of the ductus venosus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Indomethacin can cause premature closure of the ductus arteriosus if used beyond 32 weeks of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 679, Williams Obstetrics 26<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 24024,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 73689,
      "choices": [
        {
          "id": 293697,
          "text": "<p><span style=\"font-size:16px;\">Maraviroc</span></p>"
        },
        {
          "id": 293698,
          "text": "<p><span style=\"font-size:16px;\">Ibalizumab</span></p>"
        },
        {
          "id": 293699,
          "text": "<p><span style=\"font-size:16px;\">Fostemsavir</span></p>"
        },
        {
          "id": 293700,
          "text": "<p><span style=\"font-size:16px;\">Tenofovir</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">Which of the following drug binds to CD4 receptors and is used for both CCR-5 as well as CXCR-4 tropic HIV?&nbsp;(INICET NOV 2024)</span></p>",
      "unique_key": "Q6693775",
      "question_audio": null,
      "question_video": null,
      "map_id": 26885752,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. B) Ibalizumab</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Explanation:</strong>&nbsp;</span></p><p><br><span style=\"font-size:16px;\">Ibalizumab is a post-attachment inhibitor that binds to CD4 receptors. After HIV attaches to CD4 via GP120, ibalizumab prevents the conformational change in the CD4 receptor that is necessary for viral entry. Since it acts directly on CD4 receptors, it is effective against both CCR5 and CXCR4-tropic HIV strains.</span></p><p><br><span style=\"font-size:16px;\"><strong>Entry Inhibitors</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-03-08%20114941.jpg\" width=\"788\" height=\"330\"></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-03-08%20114953.jpg\" width=\"1141\" height=\"529\"></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong>&nbsp;</span></p><p><br><span style=\"font-size:16px;\"><strong>Option A. Maraviroc</strong>: This is a CCR5 co-receptor antagonist. It only works against CCR5-tropic HIV and is ineffective against CXCR4-tropic strains.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option C. Fostemsavir:</strong> This is an attachment inhibitor that binds to viral GP120, preventing initial attachment to CD4 receptors. It does not bind to CD4 receptors directly.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. Tenofovir</strong>: This is a Nucleotide Reverse Transcriptase Inhibitor (NRTI). It works after viral entry by inhibiting viral DNA synthesis. It does not affect viral entry or bind to CD4 receptors.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong>&nbsp;</span></p><p><br><span style=\"font-size:16px;\">Ibalizumab is a post-attachment inhibitor that binds to CD4 receptors and prevents HIV from entering T-cells by inhibiting conformational changes required for interaction with CCR5 and CXCR4 co-receptors. It is useful in multidrug-resistant HIV cases where other entry inhibitors like Maraviroc (CCR5-specific) are ineffective.</span><br><br><span style=\"font-size:16px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-03-08%20115024.jpg\" width=\"1106\" height=\"345\"></span></p>",
      "correct_choice_id": 293698,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 73672,
      "choices": [
        {
          "id": 293629,
          "text": "<p><span style=\"font-size:16px;\">PCT</span></p>"
        },
        {
          "id": 293630,
          "text": "<p><span style=\"font-size:16px;\">Thick ascending loop</span></p>"
        },
        {
          "id": 293631,
          "text": "<p><span style=\"font-size:16px;\">DCT</span></p>"
        },
        {
          "id": 293632,
          "text": "<p><span style=\"font-size:16px;\">Collecting duct&nbsp;</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">A person went for a trip on hills and developed difficulty breathing. He was given a diuretic which is considered as the drug of choice for this condition. What is the site of action of this drug? (FMGE JAN 2025)</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/image%20(1).jpg\" width=\"763\" height=\"590\"></span></p>",
      "unique_key": "Q7279423",
      "question_audio": null,
      "question_video": null,
      "map_id": 26886292,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. A) PCT (Proximal Convoluted Tubule)</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Explanation:&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The clinical scenario describes acute mountain sickness, characterized by breathing difficulty at high altitudes due to hypoxia. The drug of choice for both prevention and treatment of mountain sickness is acetazolamide. Acetazolamide is a carbonic anhydrase inhibitor that acts primarily in the proximal convoluted tubule (PCT). It inhibits the reabsorption of bicarbonate in the PCT, causing mild metabolic acidosis which stimulates breathing and helps acclimatization to high altitude.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option B. Thick ascending loop -&nbsp;</strong>Loop diuretics like furosemide act here, not acetazolamide<strong>&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option C. DCT (Distal Convoluted Tubule) -&nbsp;</strong>Thiazide diuretics act here, not carbonic anhydrase inhibitors&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. Collecting duct -&nbsp;</strong>Potassium-sparing diuretics and aldosterone antagonists act here, not carbonic anhydrase inhibitors</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">A carbonic anhydrase inhibitor, is the drug of choice for mountain sickness and acts in the proximal convoluted tubule.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Diuretics Classification Table</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-03-07%20165250.jpg\" width=\"858\" height=\"770\"></strong></span></p>",
      "correct_choice_id": 293629,
      "solution_audio": null,
      "solution_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/73672/FMGE_Jan_2025_Pharmacology_Q_-_5.mp4",
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "top",
      "tags": [
        "ClinicalVignette",
        "Factual",
        "FMGE",
        "ImageBased",
        "TreatmentBased"
      ],
      "explanation_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/73672/FMGE_Jan_2025_Pharmacology_Q_-_5.mp4",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52124,
      "choices": [
        {
          "id": 207997,
          "text": "<p><span style=\"font-size:12.0pt;\">NS1 Ag ELISA</span></p>"
        },
        {
          "id": 207998,
          "text": "<p><span style=\"font-size:12.0pt;\">Dengue RNA by PCR</span></p>"
        },
        {
          "id": 207999,
          "text": "<p><span style=\"font-size:12.0pt;\">Antibody detectionby ELISA</span></p>"
        },
        {
          "id": 208000,
          "text": "<p><span style=\"font-size:12.0pt;\">Viral culture</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient presented with retro-orbital pain and rash since the 5 days. Most appropriate test to be done now is:&nbsp;</span>&nbsp;(INICET MAY 2024)</p>",
      "unique_key": "Q6189532",
      "question_audio": null,
      "question_video": null,
      "map_id": 26885755,
      "difficulty_level": "intermediate",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Antibody detection by ELISA</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">When diagnosing dengue fever, the timing of the test is crucial. Dengue virus infection can be diagnosed by detecting the virus, its RNA, or its antigens, as well as by detecting antibodies against the virus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>NS1 Ag ELISA (Option A)</strong> and <strong>Dengue RNA by PCR (Option B)</strong> are methods used to detect the presence of the dengue virus or its antigens in the early stages of the infection, typically within the first 1-5 days of symptom onset. This is because the viral load and antigen levels are highest during this period.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Antibody detection by ELISA (Option C)</strong> becomes more appropriate after the initial phase of infection, typically after 5-7 days. At this point, the patient's immune system has started producing antibodies (IgM and IgG) against the virus, which can be detected using ELISA.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Viral culture (Option D)</strong>, while definitive, is not typically used in routine clinical practice due to its complexity, cost, and time requirements.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Since the patient has been symptomatic for 5 days, it is likely that antibodies have begun to be produced. Therefore, the most appropriate test at this stage is the detection of antibodies by ELISA.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. NS1 Ag ELISA</strong>: This test is most effective within the first 1-5 days of infection when the NS1 antigen is present in the blood. After this period, its sensitivity decreases.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Dengue RNA by PCR</strong>: This test is also most effective within the first 1-5 days of infection for detecting the viral RNA. After this period, the viral load decreases, making the test less effective.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Viral culture</strong>: This method is not commonly used in routine practice due to its complexity and time-consuming nature.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">For a patient presenting with dengue symptoms for more than 5 days, the most appropriate diagnostic test is antibody detection by ELISA, as antibodies are typically present after 5-7 days of infection.</span></p>",
      "correct_choice_id": 207999,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}